SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 24.90-0.4%Dec 31 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rob Loney who wrote (468)1/31/1998 5:50:00 PM
From: BigKNY3  Read Replies (1) of 9523
 
MUSE and Viagra:

The Vivus "direct to the consumer" ad and television campaign "Impotence is Optional" has begun. Here are the MUSE features that are described in the ad (some in rather small type):

-MUSE is an "urethral suppository". A MUSE applicator delivers a tiny medicated pellet to the urethra.
-MUSE was successful in about 50% of men with severe impotence.
-33% of men reported genital pain.
-7% of patients dropped out of clincial studies due to adverse reactions.
-3% of patients reported symptoms from lowering of blood pressure.
-Possible side effects to partners were vaginal itching or burning
-Patients' duration of erection have lasted for more than 4 hours. An application of ice packs may shorten the duration.
-MUSE must be stored in a refrigerator

Given the above profile, my view is reinforced that upon approval Viagra will not compete with MUSE. MUSE may find a niche in the ED market for non-responders to oral therapy...either alone or in combination with Viagra. The size of this market segment will be dependent on MUSE's efficacy in this patient group and how large the entire ED market will become with Viagra's approval.

BigKNY3
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext